Aktienanalyse zu Galapagos NV (GLPG)GLPGGalapagos NV

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer. It operates in the Healthcare sector.

Galapagos NV is not a good buy right now for a Beginner investor with a long-term focus and $50,000-$100,000 available. The stock is trading below key moving averages, lacks a current proprietary buy signal, and options sentiment is extremely bearish. While the latest quarter showed explosive revenue and earnings growth, the current setup does not offer a clean long-term entry today. I would not buy it now; I would wait for a clearer technical reversal and better sentiment.

8 analysts cover GLPG: 6 rate it Buy, 2 Hold and 0 Sell. The average price target is 30.50.